Blue Gen Therapeutics Foundation Secures Exclusive License for Promising Gene Therapy Programs from Adverum Biotechnologies

Sacramento, California – February 29, 2024 Blue Gen Therapeutics Foundation (BGTF), a non-profit organization dedicated to advancing gene therapy treatments for rare inherited retinal diseases, is proud to announce the exclusive license of two gene therapy programs from Adverum Biotechnologies (Nasdaq: ADVM). This acquisition includes the rights to ADVM-062 and ADVM-082, two innovative intravitreal gene […]

Read More